Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
3.810
-0.030 (-0.78%)
At close: Apr 14, 2026, 4:00 PM EDT
3.780
-0.030 (-0.79%)
After-hours: Apr 14, 2026, 5:25 PM EDT
Adagene Employees
Adagene had 128 employees as of December 31, 2025. The number of employees decreased by 10 or -7.25% compared to the previous year.
Employees
128
Change (1Y)
-10
Growth (1Y)
-7.25%
Revenue / Employee
$59,929
Profits / Employee
-$137,574
Market Cap
251.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -10 | -7.25% |
| Dec 31, 2024 | 138 | -36 | -20.69% |
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 147 |
| Arcturus Therapeutics Holdings | 111 |
| C4 Therapeutics | 104 |
| Alector | 103 |
| Orchestra BioMed Holdings | 86 |
| Compugen | 75 |
| Camp4 Therapeutics | 48 |
| Milestone Pharmaceuticals | 38 |
ADAG News
- 12 hours ago - Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - GlobeNewsWire
- 12 days ago - Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - GlobeNewsWire
- 12 days ago - Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - GlobeNewsWire
- 12 days ago - Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response - GlobeNewsWire
- 13 days ago - Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - GlobeNewsWire
- 2 months ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Adagene Provides Business Update and 2026 Objectives - GlobeNewsWire